Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International ConferenceBusiness Wire • 05/12/22
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term LoanBusiness Wire • 04/11/22
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With CancerBusiness Wire • 03/29/22
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/14/22
Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 03/07/22
Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park CapitalBusiness Wire • 03/07/22
Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer MeetingBusiness Wire • 03/03/22
Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022Business Wire • 02/28/22
Biodesix CEO Scott Hutton Named to The Healthcare Technology Report's List of Top 25 Biotech CEOs in 2022Business Wire • 02/22/22
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)Business Wire • 02/14/22
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 02/09/22
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to ResultsBusiness Wire • 01/18/22